Emery Pharma scientists worked with Biomed comparing their InTray® MRSA selective agar product to current market MRSA selective agars in order to evaluate diagnostic efficacy. From this research they then wrote a research article, published in the Journal of Medical Microbiology & Diagnostics. The abstract is as follows:
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most dangerous antibiotic-resistant pathogens and a common cause of most health-care acquired infections (HAIs). MRSA causes a range of illnesses, from skin and wound infections to pneumonia and bloodstream infections that can cause sepsis and ultimately lead to death. The CDC and WHO have listed MRSA as a serious threat infection and it also is included in The National Action Plan for Combating Antibiotic-resistant Bacteria. Early, reliable, and accurate diagnosis of MRSA in a clinical setting is critical for the treatment and control of infection in hospitals and the community. To address this, we comparatively evaluated the efficacy of two commercial diagnostic systems, Biomed InTray® Colorex device and the conventional BDTM ESwab Regular Collection Kit/ BBL™ CHROMagar® (ESwab + CHROMagar®) to recover 51 MRSA clinical isolates. The percentage recovery of MRSA clinical isolates in the InTray® device and in ESwab + CHROMagar® was 99% and 75%, respectively. Our findings suggest that the InTray® device was more efficient than ESwab + CHROMagar® in recovering MRSA clinical isolates.
Keywords: Methicillin-resistant Staphylococcus aureus (MRSA); diagnostic test; InTray®; Eswab+CHROMagar®
Authors: Kiran H. Bijlani, Ph.D., Marcela Gomez, B.S., Rowena Matias, B.S., Ana Najafi, B.S., Ron Najafi, Ph.D., Sridhar Arumugam, Ph.D.
Click on the front page above to read the full article, or click here to read the article on the Journal of Medical Microbiology & Diagnostics.